Published in Medical Patent Business Week, May 11th, 2007
"Trademark approval is an appropriate acknowledgment of our position as a world leader in the development of biosimulation technologies," said Guy Malchi, CEO of Optimata.
Commenting on the recent launch of the targeted therapeutics module he added: "This is a new product that enables improved predictions and better optimization for the impact and side effects of novel targeted therapy agents,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week